What's Happening?
Helical, a London-based pharma AI startup, has raised $10 million in a seed round led by redalpine, with participation from notable investors including the CEOs of Cohere and HuggingFace. The company is already collaborating with top-20 global pharma companies,
including Pfizer, to enhance drug discovery processes using bio foundation models. Helical's platform aims to bridge the gap between AI model outputs and scientific decision-making, facilitating faster and more consistent drug discovery. The funding will support the expansion of Helical's science and engineering team and further integration of AI systems in pharma research.
Why It's Important?
Helical's approach to integrating AI in pharma research could significantly reduce drug discovery timelines and costs, addressing the industry's challenge of high R&D spending and low clinical trial success rates. By providing infrastructure that enables seamless collaboration between bench scientists and ML engineers, Helical aims to improve the reproducibility and transferability of research across disease areas. This innovation has the potential to accelerate the development of new treatments, benefiting patients and healthcare systems globally.
